Lv31
310 积分 2023-11-02 加入
Therapeutic developments in pancreatic cancer
2小时前
已完结
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis
4天前
已完结
1528P TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S- 1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
10天前
已关闭
1528P TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S- 1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
10天前
已关闭
First-Line Immunotherapy for Non-Small-Cell Lung Cancer
16天前
已完结
RAS-targeted therapies: is the undruggable drugged?
19天前
已完结
Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study
19天前
已完结
Targeting KRAS in cancer
19天前
已完结
Combating KRASG12C Inhibitor Resistance
20天前
已完结
Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers
27天前
已关闭
皖公网安备34019202002308
